title: Changes in the degree of mineralization with osteoporosis and its treatment.
abstract: The diagnosis of osteoporosis is based on low bone mineral density (BMD) and/or the occurrence of fragility fractures. The majority of patients, however, have also abnormally low bone matrix mineralization. The latter is indicative of alterations in bone turnover rates and/or in kinetics of mineral accumulation within the newly formed bone matrix. Osteoporosis therapies can alter the bone matrix mineralization according to their action on bone turnover and/or mineralization kinetics. Antiresorptives, including the most widely used bisphosphonates, reduce the bone turnover rate resulting in a decrease in heterogeneity and an increase in the degree of mineralization toward to or even beyond normal values. Anabolic agents increase the bone volume and the amount of newly formed bone resulting in a likely transient decrease in mean degree and homogeneity of mineralization. Hence, the measurement of bone matrix mineralization is a sensitive tool to evaluate the response to therapy.
authors.affiliation: 1st Medical Department, Hanusch Hospital, Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, Heinrich Collin Str. 30, A-1140, Vienna, Austria, paul.roschger@osteologie.at.
authors.forename: Paul
authors.initials: P
authors.lastname: Roschger
authors.forename: Barbara
authors.initials: B
authors.lastname: Misof
authors.forename: Eleftherios
authors.initials: E
authors.lastname: Paschalis
authors.forename: Peter
authors.initials: P
authors.lastname: Fratzl
authors.forename: Klaus
authors.initials: K
authors.lastname: Klaushofer
mesh_terms: D045930:Anabolic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects / Q000502:physiology*; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002113:Calcification, Physiologic / Q000187:drug effects / Q000502:physiology*; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism; D019379:Teriparatide / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D045930:Anabolic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D019379:Teriparatide